Can Ozempic Help You Quit Smoking? GLP-1 Evidence 2026

If you take Ozempic or Wegovy and noticed you want fewer cigarettes, you are not imagining a trend: researchers are asking the same question. So, does Ozempic help you quit smoking? The honest answer in 2026 is “not proven.” Semaglutide and related GLP-1 drugs look promising in animal studies and in some early human data, but the randomized trials so far show a clearer benefit for limiting weight gain after quitting than for quitting itself.

This guide walks through what the trials, reviews and drug regulators actually say, what it means if you already use a GLP-1 medicine, and which licensed treatments you can use today. Nothing here is a reason to start or change a prescription medicine on your own.

Short answer: what GLP-1 drugs can and cannot do for smokers

GLP-1 receptor agonists are a family of injectable or oral medicines that include semaglutide (Ozempic, Wegovy, Rybelsus), liraglutide, exenatide and dulaglutide. They were developed for type 2 diabetes and later for weight management. They slow digestion, lower blood sugar and reduce appetite.

Here is where the evidence stands for smokers, in plain terms:

• Quitting: not proven. Two randomized trials pooled in a 2026 meta-analysis showed no statistically significant effect on abstinence, and the authors rated the certainty as very low.
• Craving: possible. One pilot trial of exenatide reported lower craving, and large health-record studies of semaglutide suggest fewer tobacco-related medical visits. Neither proves cause and effect.
• Weight after quitting: the most consistent finding. People on a GLP-1 drug gained less weight while they were taking it.
• Approval: none. No regulator lists smoking cessation as an approved use for any GLP-1 medicine.

That combination matters. If weight gain is the reason you keep putting off a quit attempt, this research is genuinely encouraging. If you are hoping for a shot that replaces proven stop smoking medicines, the data do not support that yet.

Why scientists think GLP-1 drugs might reduce nicotine reward

GLP-1 is a hormone made in the gut and in a small cluster of brain cells. Besides regulating appetite, it acts on reward circuits, the same systems that make nicotine, alcohol and other drugs feel rewarding.

A widely cited 2017 mouse study in Nature Neuroscience found that nicotine switches on GLP-1 neurons in the brainstem. Those neurons then signal a pathway between two small brain regions (the medial habenula and interpeduncular nucleus) that helps animals avoid taking too much nicotine. Exenatide, a GLP-1 drug, reduced nicotine intake in these mice, while mice lacking the GLP-1 receptor consumed more. The authors described GLP-1 neurons as possible “satiety sensors” for nicotine.

A 2026 review in Biological Psychiatry summarized the wider animal literature: GLP-1 drugs modulate nicotine reward, reduce nicotine self-administration and prevent the overeating that follows nicotine withdrawal. Animal results often fail to carry over to people, which is why the human trials below matter much more.

The American Society of Addiction Medicine explains the research on GLP-1 drugs in addiction, including nicotine, in this talk:

What the clinical trials found so far

Only a handful of human studies exist, and they point in different directions. The table summarizes the main ones, taken from the published abstracts.

The exenatide pilot

In the 2021 pilot, adding weekly exenatide to a nicotine patch was linked with higher abstinence, less craving at the end of treatment and less weight gain. It was small and short, and adverse events were more common on exenatide (9.5% vs 2.3%). A follow-up analysis suggested the benefit may depend on how much people smoked, depression symptoms and genetics. That is useful for designing future trials, not for choosing treatment today.

The dulaglutide trial

The largest randomized test so far is the Basel dulaglutide trial published in eClinicalMedicine. Everyone also received varenicline and counseling, and quit rates were high in both groups. Dulaglutide added nothing to abstinence at 12 weeks, 24 weeks or one year. It did stop weight gain while people were taking it.

Semaglutide: mostly observational so far

The semaglutide data that made headlines come from health records, not randomized trials. In the 2024 target-trial emulation, semaglutide users had fewer medical encounters for tobacco use disorder, and fewer cessation prescriptions and counseling sessions. The authors noted documentation bias, confounding and missing data on actual smoking, and called for clinical trials. A 2026 study of 123 people with HIV who smoked reported about 2.5 fewer cigarettes a day after starting semaglutide, but it had no comparison group.

Randomized semaglutide trials are under way. ClinicalTrials.gov lists a Canadian feasibility trial adding semaglutide to combination NRT in people with diabetes, a US pilot in adults with obesity, and a US trial of semaglutide 2.4 mg for weight after quitting. Until these report, nobody can say how well semaglutide helps people stop.

Weight gain after quitting: the strongest case for GLP-1s

Fear of gaining weight keeps many people smoking, and the trials show why it is a reasonable worry. In the placebo group of the dulaglutide trial, people gained almost 2 kg in 12 weeks, and about 3 kg by one year.

GLP-1 drugs consistently blunted that gain while people were on them. The catch is that the benefit faded once treatment stopped: at one year, weight gain was similar in both dulaglutide groups. The researchers suggested longer treatment in future studies, because weight gain after quitting is highest in the first year.

That is exactly what the Semaglutide for Post-Smoking Cessation Weight Management trial is testing. Its published protocol describes 28 weeks of semaglutide 2.4 mg or placebo for smokers with obesity or overweight, alongside nicotine patches and counseling, with weight change as the main outcome.

Weight gain is also manageable without a GLP-1 drug. Our guide to quitting without gaining weight covers meals, snacking and activity, and the health gain from stopping smoking far outweighs a few kilograms.

Is Ozempic approved for quitting smoking?

No. No regulator has approved any GLP-1 medicine as a stop smoking treatment:

• US (FDA): the current Ozempic prescribing information lists blood sugar control in adults with type 2 diabetes and reducing heart and kidney risks in some of those adults. Wegovy is approved for weight management and for cutting cardiovascular risk in people with heart disease and excess weight.
• EU (EMA): Ozempic is authorized to treat adults whose type 2 diabetes is not well controlled.
• UK (NHS): the NHS semaglutide page describes Wegovy for obesity and Ozempic and Rybelsus for type 2 diabetes, available only on prescription.

Semaglutide must not be taken to quit smoking unless a prescriber has decided it is right for you for a licensed reason. The FDA label carries a boxed warning about thyroid C-cell tumors seen in rodents. The NHS lists nausea, vomiting, constipation and diarrhea as common side effects, and warns that some websites sell fake weight-loss medicines. Buying semaglutide online to “try it for smoking” is not safe.

If you already take Ozempic or Wegovy and smoke

You may be in the best position of anyone reading this. You already have a prescriber, and your medicine may soften the post-quit weight gain that trips so many people up. Here is how to use that:

1. Tell your prescriber you want to quit. Ask which stop smoking medicine suits you alongside your GLP-1 drug. Our guide on how quitting changes medication doses explains why some medicines need reviewing when you stop smoking.
2. Do not change your GLP-1 dose on your own. The NHS advises against stopping semaglutide suddenly, especially with type 2 diabetes.
3. Add a licensed stop smoking treatment. Nothing in the trials suggests a GLP-1 drug should replace one. In the dulaglutide trial, the high quit rates in both groups came with varenicline and counseling.
4. Watch your blood sugar if you have diabetes. Our step-by-step plan for quitting with type 2 diabetes covers monitoring and appointments.
5. Separate nausea from withdrawal. GLP-1 side effects and nicotine withdrawal can both upset your stomach. Noting when symptoms start helps your clinician tell them apart.

A craving log helps here. In iQuit you can record each craving with its trigger and intensity and keep a mood journal, so you and your clinician can see whether urges really are fading.

Licensed treatments that work today

While GLP-1 research continues, proven options are available now. The FDA says approved and cleared cessation products can even double your chance of quitting successfully. In England, NICE guideline NG209 advises that the following, combined with behavioral support, are more likely to work.

In the US, the FDA has approved two non-nicotine pills, varenicline and bupropion, plus nicotine patches, gum and lozenges over the counter and nicotine spray and inhaler on prescription. Read more about varenicline, the most effective licensed pill, and bupropion, or see quit-smoking pills compared side by side. If you choose patches, our guide to nicotine patch side effects explains what is normal.

Stopping smoking also cuts your risk of heart disease and stroke, the same risks many GLP-1 users are already treating. If you have had a stroke, read about quitting smoking after a stroke.

Ozempic and Smoking FAQ